摘要
本文以胸腺五肽注射剂不同厂家规格招标及临床应用情况为研究对象,通过对胸腺五肽注射剂用药情况的分析发现,目前药品招标采购的原则有待商榷,以药养医、药品销售不正当竞争是药价虚高的主要原因,临床合理用药监管力度有待加强。
To research different manufacturer specifications bidding and clinical application of the Thymopentin Injections. By the analysis of Thymopentin Injections' application,it's found that the principle of collective-bidding and purchase for medicine remain to be discussed at present.The main reasons for the virtualhigh prices are the drug-maintaining-medicine and pharmaceutical sales with unfair competition.Clinical rational drug use supervision needs to be strengthened.
出处
《中国医疗保险》
2012年第4期57-59,共3页
China Health Insurance
关键词
胸腺五肽注射剂
药品管理
医疗保险
thymopentin injections, drug management, medical insurance